title: A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.
abstract: We report a case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a complete response to trastuzumab and paclitaxel treatment. A 37-year-old woman was referred to our hospital for right breast swelling with broad skin redness and right axillary tumor. Ipsilateral infraclavicular and contralateral axillary lymph nodes swelling were also recognized. The histopathological findings of core-needle biopsy specimens from primary breast tumor and ipsilateral axillary lymph node were invasive ductal carcinoma with a micropapillary component. Immunohistochemical examination gave a negative result for estrogen receptor (ER)/progesterone receptor (PgR), and overexpression of HER-2 (Hercep Test 3+). Advanced inflammatory breast cancer with an invasive micropapillary component was diagnosed (T4d N3 M1 (LYM), stage IV). The patient was treated with combination chemotherapy using weekly paclitaxel and trastuzumab. After administration of three courses, the breast swelling, skin redness, and lymph node swelling disappeared completely. She maintained complete remission of disease for 12 months and was judged to have a clinically complete response by the RECIST criteria. Invasive micropapillary carcinoma is known to be an aggressive histological type associated with a high incidence of lymph node metastasis and poor prognosis. This is the first reported case of advanced inflammatory breast cancer with an invasive micropapillary component showing a clinically complete response to trastuzumab-containing treatment. This report suggests trastuzumab-containing chemotherapy is a promising therapy for HER-2-positive advanced invasive micropapillary carcinoma.
authors.affiliation: Department of Breast Oncology, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan. shigematu1330@yahoo.co.jp
authors.forename: Hideo
authors.initials: H
authors.lastname: Shigematsu
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Kimihiro
authors.initials: K
authors.lastname: Tanaka
authors.forename: Satoko
authors.initials: S
authors.lastname: Shiotani
authors.forename: Chinami
authors.initials: C
authors.lastname: Koga
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Kawaguchi
authors.forename: Sumiko
authors.initials: S
authors.lastname: Nishimura
authors.forename: Kenichi
authors.initials: K
authors.lastname: Taguchi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Nishiyama
authors.forename: Shinji
authors.initials: S
authors.lastname: Ohno
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002291:Carcinoma, Papillary / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D058922:Inflammatory Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008207:Lymphatic Metastasis; D017239:Paclitaxel / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D000068878:Trastuzumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab
references.citation: Clin Transl Oncol. 2006 Oct;8(10):761-3
references.pmid: 17074677
references.citation: Histopathology. 2004 Apr;44(4):332-8
references.pmid: 15049898
references.citation: Gan To Kagaku Ryoho. 2007 Jan;34(1):65-8
references.pmid: 17220672
references.citation: Ann Diagn Pathol. 2009 Jun;13(3):151-7
references.pmid: 19433292
references.citation: J Clin Oncol. 2005 Aug 1;23(22):5117-25
references.pmid: 15955906
references.citation: Am J Clin Pathol. 2006 Nov;126(5):740-6
references.pmid: 17050071
references.citation: Histopathology. 2004 Jan;44(1):18-23
references.pmid: 14717664
references.citation: Int J Surg Pathol. 2008 Apr;16(2):155-63
references.pmid: 18417672
references.citation: N Engl J Med. 2005 Oct 20;353(16):1673-84
references.pmid: 16236738
references.citation: Am J Clin Pathol. 2004 Jun;121(6):857-66
references.pmid: 15198358
references.citation: Pathol Res Pract. 1994 Aug;190(7):668-74
references.pmid: 7808965
references.citation: Arch Pathol Lab Med. 2005 Oct;129(10):1277-82
references.pmid: 16196516
references.citation: N Engl J Med. 1998 Oct 1;339(14):974-84
references.pmid: 9753714
references.citation: Pathol Int. 2004 Feb;54(2):90-6
references.pmid: 14720138
references.citation: J Clin Oncol. 2005 Jul 1;23(19):4247-50
references.pmid: 15911863
references.citation: N Engl J Med. 2005 Oct 20;353(16):1659-72
references.pmid: 16236737
references.citation: Hum Pathol. 1999 Dec;30(12):1459-63
references.pmid: 10667424
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153